BACKGROUND: Testicular cancer is associated with excellent prognosis and cure is achieved in most patients with advanced cancer treated with cisplatin-based chemotherapy. However, testicular cancer survivors are at increased risk of accelerated atherosclerosis, which significantly contributes to their late morbidity and mortality. Atherosclerosis is associated with a higher proportion of fat mass and especially with increased amount of visceral fat. We explored the effects of cisplatin-based chemotherapy on body composition during and after the treatment. PATIENTS AND METHODS: We studied 30 testicular cancer patients before chemotherapy, after the second cycle of chemotherapy and three months after the end of chemotherapy. Body composition parameters were evaluated using bioelectrical impedance analysis (BIA). RESULTS: Three months after the end of chemotherapy the fat mass had increased from 22.04±7.15% to 23.92±7.33% (P=0.026) and visceral fat volume had increased by 17% from 2.36±1.75l to 2.77±1.94l (P=0.013). In the whole sample there was a decrease in muscle mass after the second cycle of chemotherapy (-1.33 ± 2 kg on average; P=0.005). The changes in body composition varied according to distinct baseline fat mass. CONCLUSION: Cisplatin-based chemotherapy was associated with increase of fat mass, visceral fat, and body mass index. We also observed decrease in muscle mass and total body water. Our results suggest that BIA could help to target preventative measures to avert the acceleration of atherosclerosis in patients treated with cisplatin-based chemotherapy.

Department of Internal Medicine 3rd Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer Hospital Prague Czech Republic

Nutrition Centre Thomayer Hospital Prague Czech Republic

Zobrazit více v PubMed

Dušek L, Mužík J, Gelnarová E, Fínek J, Vyzula R, Abrahámová J. Cancer Incidence and Mortality in the Czech Republic. Klin Onkol 2010;23(5):311-24. PubMed

Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, McGlynn KA. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev 2010;19(5):1151-9. DOI

Hashibe M, Abdelaziz S, Al-Temimi M, Fraser A, Boucher KM, Smith K, et al. Long-term health effects among testicular cancer survivors. J Cancer Surviv 2016;10(6):1051-7. PubMed DOI

Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, Willemse PB, Mulder NH, van den Berg MP, Schraffordt H, Sleijfer DT. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18(8):1725-32. DOI

Nuver J, Smit AJ, Wolffenbuttel BH, Sluiter WJ, Hoekstra HJ, Sleijfer DT, Gietema JA. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23(16):3718-25. DOI

Nord C, Fosså SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 2003;88(1):36-41. DOI

Sagstuen H, Aass N, Fosså SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005;23(22):4980-90. PubMed DOI

Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Daernaly DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21(8):1513-23. PubMed DOI

van Den Belt-Dusebout AW, Nuver J, de Wit R, Gietema JA, Ten Bokkel Huinink WW, Rodrigus PT, Schimmel EC, Aleman BM, Leeuven FE, Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24(3):467-75. DOI

Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, Wilsgaard T, Bremnes RM, Fossa SD. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 2010;28(30):4649-57. DOI

Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008;112(9):1949-53. PubMed DOI

Van Den Belt-Dusebout AW, De Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, Hoekstra HJ, Ouwens GM, Aleman BM, van Leeuwen FE. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007;25(28):4370-8. DOI

Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy fortesticular cancer. J Clin Oncol 1996;14(11):2923-32. DOI

Nuver J, De Haas EC, Van Zweeden M, Gietema JA, Meijer C. Vascular damage in testicular cancer patients: A study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010;23(1):247-53. PubMed DOI

Halpern-Silveira D, Susin LR, Borges LR, Paiva SI, Assunção MC, Gonzalez MC. Body weight and fat-free mass changes in a cohort of patients receiving chemotherapy. Support Care Cancer 2010;18(5):617-25. PubMed DOI

Isenring E, Bauer J, Capra S, Davies PS. Evaluation of foot-to-foot bioelectrical impedance analysis for the prediction of total body water in oncology outpatients receiving radiotherapy. Eur J Clin Nutr 2004;58(1):46-51. PubMed DOI

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn G, Cedermark-Cohn, Horwich A, Klepp O, Laguna MP, Pizzocaro G. European association of urology, Guidelines EUS pro diagnostiku, klasifikaci a léčbu testikulárního karcinomu. Urol List 2006;4(3):61-86.

Bioelectrical impedance analysis measurement procedure by the Medical Body Composition Analyzer Seca 515. NIHR Southampton Biomedical Research Centre 2014, Available from: https://www.uhs.nhs.uk/Media/Southampton-Clinical-Research/Procedures/BRCProcedures/Procedure-for-bioimpedance-using-the-Seca-mBCA.pdf

Gould H, Brennan SL, Kotowicz MA, Nicholson GC, Pasco JA. Total and appendicular lean mass reference ranges for Australian men and women: The Geelong osteoporosis study. Calcif Tissue Int 2014;94(4):363-72. PubMed DOI

Fosså SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, Jonesuu H, Andersson M, Kajser M, Gospodarowicz M, Cohen R, Pukkala E, Travis LB. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007;99(7):533-44. DOI

Freedman RJ, Aziz N, Albanes D, Hartman T, Danforth D, Hill S, Sebring N, Reynolds JC, Yanovsky JA, Weight and Body Composition Changes during and after Adjuvant Chemotherapy in Women with Breast Cancer. J Clin Endocrinol Metab 2004;89(5):2248-53. PubMed DOI

Head GA. Cardiovascular and metabolic consequences of obesity. Front Physiol 2015;6:32. PubMed DOI

Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14(12):1132-43. DOI

Brook RD, Bard RL, Rubenfire M, Ridker PM, Rajagopalan S. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweight adults. Am J Cardiol 2001;88(11):1264-9. DOI

Öhman MK, Shen Y, Obimba CI, Wright AP, Warnock M, Lawrence DA, Eitzman DT. Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2008;117(6):798-805. DOI

Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr Opin Support Palliat Care 2018;12(4):420-26. PubMed DOI

Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins 2010;2(11):2490-518. PubMed DOI

Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23(5):460-4. PubMed DOI